具体实施方式
本申请所涉及的化合物及其药学可接受的盐的代谢产物,以及可以在体内转变为本申请所涉及的化合物及其药学可接受的盐的结构的前药,也包含在本申请的权利要求中。
以下实施例对本发明做进一步的描述,但该实施例并非用于限制本发明的保护范围。
实施例1
4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
步骤1.
5-溴-2-氯-N-甲氧基-N-甲基烟酰胺
5-bromo-2-chloro-N-methoxy-N-methylnicotinamide
将5-溴-2-氯烟酸96g(294.07mmol)溶于1L二氯甲烷,搅拌下加入N,O-二甲基羟胺盐酸盐31.45g(323.48mmol),EDC盐酸盐62g(323.48mmol),最后滴加三乙胺39.2g(388.17mmol),搅拌过夜,反应液水洗,饱和食盐水洗,有机相用无水硫酸钠干燥,减压旋干溶剂,柱层析得到产物白色固体65g(79%)。
1HNMR(400MHz,CDCl3),δppm 8.48(d,J=2.0Hz,1H),7.79(s,1H),3.51(s,3H),3.37(s,3H).MS(ESI),m/z:279(M+).
步骤2.
1-(5-溴-2-氯苯基)乙酮
1-(5-bromo-2-chlorophenyl)ethanone
1L的三颈瓶中,将化合物225g(89.75mmol)溶于400mL无水四氢呋喃,冷却至-40℃,搅拌下缓慢滴加CH3MgBr(3M,***溶液)35.9mL(107.7mmol),滴加完毕,维持-40℃1小时,随后升至室温搅拌3小时,冰浴冷却下,加入饱和氯化铵水溶液,乙酸乙酯萃取,有机相水洗,饱和食盐水洗,无水硫酸钠干燥,减压旋干溶剂,硅胶快速柱层析得到浅红色油状物17.7g(84%)。
1HNMR(400MHz,CDCl3),δppm 8.53(d,J=2.0Hz,1H),8.00(d,J=2.0Hz,1H),2.69(s,3H).MS(ESI),m/z:234(M++H+).
步骤3.
5-溴-3-甲基-1H-吡唑并[3,4-b]吡啶
5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine
将17.7g化合物3(75.6mmol),80%水合肼9.4g(151.3mmol),碳酸钾10.4g(75.6mmol)加入200mL四氢呋喃中,加热回流过夜,旋掉大部分溶剂,加水,乙酸乙酯萃取,有机相水洗,饱和食盐水洗,无水硫酸钠干燥,旋干溶剂得到浅黄色固体15.3g(95.4%)。
1HNMR(400MHz,d-DMSO),δppm 13.42(s,1H),8.52(s,2H),2.51(s,3H).
MS(ESI),m/z:213(M++H+).
步骤4.
5-溴-3-甲基-1-(2-三甲基硅乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶
5-bromo-3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine
将15.3g化合物4(72.17mmol)溶于100mL DMF,冰浴冷却,搅拌下分批加入60%氢化钠8.66g(216.51mmol),搅拌10min,滴加三甲基硅基乙氧甲基氯20.5g(122.69mmol),滴加完毕升至室温搅拌过夜,加水,乙酸乙酯萃取,有机相水洗三次,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得到浅黄色色油状物20.8g(84%)。
1HNMR(400MHz,CDCl3),δppm 8.55(d,J=2.0Hz,1H),8.12(d,J=2.0Hz,1H),5.76(s,2H),3.62(t,J=8.4Hz,2H),2.55(s,3H),0.93(t,J=8.4Hz,2H),-0.05(s,9H).
MS(ESI),m/z:343(M++H+).
步骤5.
4-甲基-3-((三甲基硅基)乙炔基)苯甲酸甲酯
methyl 4-methyl-3-((trimethylsilyl)ethynyl)benzoate
5L三颈瓶中,加入化合物6300g(1087mmol),碘化亚铜2.06g(10.87mmol),二(三苯基膦)二氯化钯7.63g(10.87mmol),乙酸乙酯4L,三乙胺329.3g(3260mmol),三甲基硅乙炔159.8g(1630mmol),置换氩气,封闭反应体系,室温搅拌过夜。过滤反应液,滤液水洗,饱和食盐水洗,有机相无水硫酸钠干燥,旋干溶剂得红色固体267.4g(100%)。
1HNMR(400MHz,CDCl3),δppm 8.10(d,J=1.6Hz,1H),7.86(dd,J=8.0,2.0Hz,1H),7.26(d,J=8.0Hz,1H),3.89(s,3H),2.48(s,3H),0.19(s,9H).
MS(ESI),m/z:247(M++H+).
步骤6.
3-乙炔基-4-甲基苯甲酸甲酯
methyl 3-ethynyl-4-methylbenzoate
5L三颈瓶中,加入化合物7267.4g(1087mmol),再加入甲醇4L,机械搅拌使其溶解,加入碳酸钾225g(1630mmol),5-10min反应完毕,将反应液倾入5L水中,搅拌均匀,过滤沉淀,水洗,固体真空干燥,得到棕色固体180g(95%)。
1HNMR(400MHz,CD3OD),δppm 8.13(s,1H),7.90(d,J=8.0Hz,1H),7.27(d,J=8.0Hz,1H),3.90(s,3H),3.34(s,1H),2.50(s,3H).
MS(ESI),m/z:175(M++H+).
步骤7.
4-甲基-3-((3-甲基-1-(2-三甲基硅乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)苯甲酸甲酯methyl 4-methyl-3-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzoate
100mL单颈瓶中加入化合物510g(29.24mmol),化合物85.09g,碘化亚铜56mg(0.2924mmol),二(三苯基膦)二氯化钯205mg(0.2924mmol),二异丙基乙基胺7.54g(58.48mmol),N-甲基吡咯烷酮30mL,置换氩气,80℃搅拌过夜,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,有机相无水硫酸钠干燥,旋干溶剂,柱层析得白色固体3.82g(54%)。
1HNMR(400MHz,CDCl3),δppm 9.54(d,J=2.0Hz,1H),8.20(d,J=2.0Hz,1H),8.18(d,J=1.6Hz,1H),7.92(m,1H),7.31(m,1H),5.80(s,1H),3.93(s,3H),3.64(t,J=8.4Hz,2H),2.60(s,6H),0.95(m,2H),-0.05(s,9H).
MS(ESI),m/z:436(M++H+).
步骤8.
4-甲基-3-((3-甲基-1-(2-三甲基硅乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-三氟甲基苯基)苯甲酰胺
4-methyl-3-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethyny
l)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
将化合物9200mg(0.4591mmol)和化合物10 125mg(0.4591mmol)溶于2.5mL四氢呋喃中,搅拌,降温至-20℃,将叔丁醇钾155mg(1.378mmol)溶于2.5mL四氢呋喃中,缓慢滴加至前述混合液中,滴加完毕维持-20℃30min,然后升至室温搅拌2h,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,无水硫酸钠干燥,旋干溶剂,柱层析得浅黄色固体204mg(65.6%)。
1HNMR(400MHz,CDCl3),δppm 8.69(d,J=2.0Hz,1H),8.16(d,J=2.0Hz,1H),8.02(d,J=1.6Hz,1H),7.98(s,1H),7.90(m,1H),7.85(d,J=2.0Hz,1H),7.79(s,1H),7.77(s,1H),7.39(d,J=8.0Hz,2H),5.80(s,2H),3.66(m,4H),2.61(s,3H),2.58(s,3H),2.44(br,4H),2.31(s,3H),0.93(m,2H),-0.05(s,9H).
MS(ESI),m/z:677(M++H+).
步骤9.
4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
将化合物11 204mg(0.3014mmol)溶于5mL 1M的四丁基氟化铵的四氢呋喃溶液中,搅拌下,加热回流过夜,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,无水硫酸钠干燥,旋干溶剂,柱层析得浅黄色固体126mg(76.5%)。
1HNMR(400MHz,d-DMSO),δppm 13.52(s,1H),10.57(s,1H),8.69(d,J=2.0Hz,1H),8.22(d,J=2.0Hz,1H),8.18(d,J=2.0Hz,1H),8.07(d,J=8.8Hz,1H),7.93(d,J=7.6Hz,1H),7.70(m,2H),7.52(d,J=8.0Hz,1H),3.56(m,2H),2.59(s,3H),2.51(s,3H),2.33(brs,8H),2.15(m,3H).
MS(ESI),m/z:547(M++H+).
实施例2
N-(3-(1H-咪唑-1-基)-5-(三氟甲基)苯基)-4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)苯甲酰胺
N-(3-(1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.75(s,1H),8.69(d,J=2.0Hz,1H),8.52(d,J=2.0Hz,1H),8.34(s,2H),8.22(s,2H),7.95(d,J=8.0Hz,1H),7.79(s,2H),7.56(d,J=8.0Hz,1H),7.17(s,1H),2.60(s,3H),2.53(s,3H).
MS(ESI),m/z:501(M++H+).
实施例3
4-甲基-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)苯甲酰胺
4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.72(s,1H),8.70(d,J=1.6Hz,1H),8.52(d,J=1.6Hz,1H),8.30(s,1H),8.21(s,2H),8.17(s,2H),7.95(m,2H),7.74(s,2H),7.56(d,J=8.0Hz,1H),7.49(s,2H),2.60(s,3H),2.54(s,3H),2.19(s,3H).
MS(ESI),m/z:515(M++H+).
实施例4
N-(3-(1H-1,2,4-三氮唑-1-yl)-5-(三氟甲基)苯基)-4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)苯甲酰胺
N-(3-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl)-4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.50(s,1H),10.83(s,1H),9.47(s,1H),8.70(m,2H),8.52(d,J=1.6Hz,1H),8.32(s,2H),8.30(s,1H),8.24(d,J=1.6Hz,1H),8.04(s,1H),7.97(m,2H),7.55(d,J=8.0Hz,1H),2.60(s,3H),2.54(s,3H).
MS(ESI),m/z:502(M++H+).
实施例5
4-甲基-N-(3-(3-甲基-1H-1,2,4-三氮唑-1-基)-5-(三氟甲基)苯基)-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)苯甲酰胺
4-methyl-N-(3-(3-methyl-1H-1,2,4-triazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.79(s,1H),9.32(s,1H),8.69(m,2H),8.52(d,J=1.6Hz,1H),8.39(s,1H),8.35(s,1H),7.97(m,2H),7.55(d,J=8.0Hz,1H),2.60(s,3H),2.54(s,3H).
MS(ESI),m/z:516(M++H+).
实施例6
4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(3-(噁唑2-基)-5-(三氟甲基)苯基)苯甲酰胺
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(3-(oxazol-2-yl)-5-(trifluoromethyl)phenyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.77(s,1H),8.80(s,1H),8.69(d,J=1.6Hz,1H),8.51(d,J=2.0Hz,1H),8.41(s,2H),8.32(s,1H),8.23(d,J=1.6Hz,1H),7.95(m,2H),7.54(d,J=8.0Hz,1H),7.47(s,1H),2.60(s,3H),2.53(s,3H).MS(ESI),m/z:502(M++H+).
实施例7
4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-(吡咯烷-1-基亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-(pyrrolidin-1-ylmethyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.50(s,1H),10.67(s,1H),8.69(d,J=1.6Hz,1H),8.52(d,J=1.6Hz,1H),8.29(s,1H),8.20(d,J=1.6Hz,1H),8.15(s,1H),7.95(m,1H),7.54(d,J=8.0Hz,1H),3.15(m,2H),2.60(s,3H),2.56(s,3H),1.85(brs,4H),1.56(m,2H),1.32(m,2H).
MS(ESI),m/z:518(M++H+).
实施例8
4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-(***啉亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-(morpholinomethyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.54(s,1H),8.69(d,J=2.0Hz,1H),8.52(d,J=2.0Hz,1H),8.22(d,J=2.0Hz,1H),8.18(d,J=2.0Hz,1H),8.08(d,J=8.0Hz,1H),7.92(dd,J=8.0,2.0Hz,1H),7.74(d,J=8.8Hz,1H),7.53(d,J=8.4Hz,1H),3.60(s,3H),3.58(s,3H),2.59(s,2H),2.54(m,4H),2.39(s,4H).MS(ESI),m/z:534(M++H+).
实施例9
(S)-N-(4-((3-(二甲氨基)吡咯烷-1-基)亚甲基)-3-(三氟甲基)苯基)-4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)苯甲酰胺
(S)-N-(4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.50(s,1H),10.54(s,1H),8.69(d,J=1.6Hz,1H),8.52(d,J=2.0Hz,1H),8.20(m,1H),8.07(d,J=7.6Hz,1H),7.92(d,J=8.0Hz,1H),7.70(d,J=8.4Hz,1H),7.53(d,J=8.0Hz,1H),3.67(m,2H),2.69(m,3H),2.59(s,3H),2.53(s,3H),2.33(m,1H),1.89(m,1H),1.63(m,1H).
MS(ESI),m/z:561(M++H+).
实施例10
4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-哌啶-1-基亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-(piperidin-1-ylmethyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.57(s,1H),8.69(d,J=2.0Hz,1H),8.52(d,J=1.6Hz,1H),8.23(s,1H),8.18(s,2H),8.09(d,J=8.0Hz,1H),7.93(m,1H),7.74(m,1H),7.63(m,1H),7.53(d,J=8.4Hz,1H),3.17(s,2H),2.59(s,3H),2.54(s,3H),2.45(brs,4H),1.55(brs,4H),1.43(brs,2H).MS(ESI),m/z:532(M++H+).
实施例11
3-((3-环丙基-1H-吡唑并[3,4-b]吡啶-5-yl)乙炔基)-4-甲基-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-三氟甲基苯基)苯甲酰胺
3-((3-cyclopropyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
步骤1.
5-溴-3-碘-1H-吡唑并[3,4-b]吡啶
5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine
将化合物1 10g(50.25mmol)和N-碘代丁二酰亚胺12g(53.34mmol)溶于300mL 1,2-二氯乙烷中,加热回流过夜,用1L四氢呋喃稀释,饱和硫代硫酸钠水溶液洗,水洗,饱和食盐水洗,有机相无水硫酸钠干燥,减压旋去溶剂得浅黄色固体15g(92%)。
1HNMR(400MHz,d-DMSO),δppm 14.31(s,1H),8.63(d,J=2.0Hz,1H),8.18(d,J=1.6Hz,1H).MS(ESI),m/z:325(M++H+).
步骤2.
5-溴-3-碘-1-(2-三甲基硅乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶
5-bromo-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine
将2.68g化合物2(8.27mmol)溶于25mLDMF,冰浴冷却,搅拌下分批加入60%氢化钠1g(24.8mmol),搅拌10min,滴加三甲基硅基乙氧甲基氯2.33g(14mmol),滴加完毕升至室温搅拌过夜,加水,乙酸乙酯萃取,有机相水洗三次,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得到浅黄色油状物3.07g(82%)。
1HNMR(400MHz,CDCl3),δppm 8.60(d,J=2.0Hz,1H),7.96(d,J=1.6Hz,1H),5.81(s,2H),3.65(m,2H),0.92(m,2H),-0.05(s,9H).
MS(ESI),m/z:455(M++H+).
步骤3.
5-溴-3-环丙基-1-(2-三甲基硅乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶
5-bromo-3-cyclopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine
将1g化合物3(2.2mmol),190mg环丙基硼酸(2.2mmol),1.18g磷酸钾,180mg[1,1’-双(二苯基膦)二茂铁]二氯化钯二氯甲烷络合物(0.22mmol)混于10mL 1,4-二氧六环中,置换氩气,90℃搅拌4h,加水,乙酸乙酯萃取,有机相水洗三次,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得到白色固体580mg(71.8%)。
1HNMR(400MHz,CDCl3),δppm 8.53(d,J=2.0Hz,1H),8.17(d,J=2.0Hz,1H),5.73(s,2H),3.60(m,2H),2.15(m,1H),1.07(m,4H),0.91(m,2H),-0.04(s,9H).
MS(ESI),m/z:369(M++H+).
步骤4.
3-((3-环丙基-1-(2-三甲基硅乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-4-甲基-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
3-((3-cyclopropyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
10mL单颈瓶中加入化合物5213mg(0.5177mmol),化合物4190mg(0.5177mmol),碘化亚铜1mg(0.005mmol),二(三苯基膦)二氯化钯4mg(0.005mmol),二异丙基乙基胺134mg(1.0354mmol),DMF 2mL,置换氩气,80℃搅拌过夜,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,有机相无水硫酸钠干燥,旋干溶剂,柱层析得浅黄色固体196mg(54%)。
1HNMR(400MHz,CDCl3),δppm 8.67(d,J=2.0Hz,1H),8.21(d,J=2.0Hz,1H),8.02(d,J=2.0Hz,1H),7.95(s,1H),7.91(d,J=2.0Hz,1H),7.89(d,J=2.0Hz,1H),7.86(d,J=2.0Hz,1H),7.78(dd,J=8.0,2.0Hz,1H),7.39(d,J=8.0Hz,1H),5.77(s,2H),3.64(m,4H),2.62(s,3H),2.58(brs,8H),2.31(s,3H),2.21(m,1H),1.12(m,4H),0.94(s,2H),-0.04(s,9H).
MS(ESI),m/z:703(M++H+).
步骤5.
3-((3-环丙基-1H-吡唑并[3,4-b]吡啶-5-yl)乙炔基)-4-甲基-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-三氟甲基苯基)苯甲酰胺
3-((3-cyclopropyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
将化合物6 190mg(0.2707mmol)溶于5mL 1M的四丁基氟化铵的四氢呋喃溶液中,搅拌下,加热回流过夜,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,无水硫酸钠干燥,旋干溶剂,柱层析得浅黄色固体108mg(70%)。
1HNMR(400MHz,d-DMSO),δppm 13.45(s,1H),10.54(s,1H),8.68(d,J=1.6Hz,1H),8.55(d,J=1.6Hz,1H),8.22(s,1H),8.19(s,1H),8.07(d,J=8.8Hz,1H),7.91(d,J=8.0Hz,1H),7.70(m,1H),7.53(d,J=8.0Hz,1H),3.57(m,2H),2.60(m,3H),2.36(m,8H),2.19(s,3H),1.67(m,1H),1.33(m,4H).
MS(ESI),m/z:573(M++H+).
实施例12
4-甲基-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)-3-((3-苯基-1H-吡唑[3,4-b]吡啶-5-基)乙炔基)苯甲酰胺
4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-phenyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例11
1HNMR(400MHz,d-DMSO),δppm 14.12(s,1H),10.55(s,1H),8.84(d,J=2.0Hz,1H),8.79(d,J=2.0Hz,1H),8.21(s,2H),8.19(m,3H),7.93(d,J=8.0Hz,1H),7.71(d,J=8.0Hz,1H),7.55(m,3H),7.45(d,J=8.0Hz,1H),3.57(m,2H),2.67(m,3H),2.40(m,8H),2.17(s,3H).
MS(ESI),m/z:609(M++H+).
实施例13
4-乙基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-ethyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
步骤1.3-氨基-4-乙基苯甲酸(3-amino-4-ethylbenzoic acid)
将15mL发烟硝酸倒入50mL单口瓶中,冷却至-5℃,搅拌下加入2g对乙基苯甲酸(13.3mmol),-5℃下继续搅拌1h,将反应液倾入冰水中,析出白色沉淀,抽滤,水洗,收集固体,真空干燥得白色固体2.6g。将2.6g化合物2(13.3mmol)溶解在20mL甲醇中,搅拌下加入300mg 50%钯碳,抽真空,置换氢气,室温搅拌过夜,反应液用硅藻土过滤,减压旋去溶剂得浅黄色固体2g(91%)。
1HNMR(400MHz,d-DMSO),δppm 7.23(s,1H),7.10(dd,J=8.0,1.6Hz,1H),7.00(d,J=8.0Hz,1H),2.47(m,2H),1.13(m,3H).
MS(ESI),m/z:166(M++H+).
步骤2.4-乙基-3-碘苯甲酸(4-ethyl-3-iodobenzoic acid)
将2g化合物3(12.1mmol)置于100mL单颈瓶中,加入28mL水,冰浴下滴加浓盐酸8.4mL,搅拌10min,缓慢滴入2mL含有0.85g亚硝酸钠(12.3mmol)的水溶液,冰浴下搅拌5min后再滴入5mL含碘化钾2.05g(12.3mmol)的水溶液,室温搅拌过夜,加水,乙酸乙酯萃取,有机相水洗,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得到白色固体2.3g(69%)。
1HNMR(400MHz,d-DMSO),δppm 13.22(s,1H),8.30(d,J=1.6Hz,1H),7.88(dd,J=8.0,1.6Hz,1H),7.42(d,J=8.0Hz,1H),2.70(m,2H),1.18(m,3H).
MS(ESI),m/z:277(M++H+).
步骤3.4-乙基-3-碘苯甲酸甲酯(methyl 4-ethyl-3-iodobenzoate)
将2.3g化合物4(8.33mmol)溶于50mL甲醇中,加入0.5mL浓硫酸,加热回流过夜,反应液冷却至室温,旋去大部分甲醇,加水,乙酸乙酯萃取,有机相水洗,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得浅黄色油状物2.4g(99%)。
1HNMR(400MHz,CDCl3),δppm 8.46(d,J=2.0Hz,1H),7.93(dd,J=8.0,1.6Hz,1H),7.28(d,J=8.0Hz,1H),3.90(s,1H),2.77(m,2H),1.23(m,3H).
MS(ESI),m/z:291(M++H+).
步骤4.4-乙基-3-碘-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
(4-ethyl-3-iodo-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide)
将1.1g化合物5(3.79mmol)和1g化合物6(3.79mmol)溶于10mL四氢呋喃,将溶有2.5g叔丁醇钾(22.3mmol)的10mL四氢呋喃溶液缓慢滴入反应瓶中,反应10min,反应液投入冰水中,乙酸乙酯萃取,有机相水洗,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得到浅黄色固体2g(99%)。
MS(ESI),m/z:532(M++H+).
步骤5.4-乙基-3-乙炔基-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
(4-ethyl-3-ethynyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide)
50mL单颈瓶中,加入化合物72g(3.77mmol),碘化亚铜7mg(0.0377mmol),二(三苯基膦)二氯化钯26mg(0.0377mmol),乙腈20mL,二异丙基乙胺1.95g(15.08mmol),三甲基硅乙炔740mg(7.54mmol),置换氩气,封闭反应体系,室温搅拌过夜。过滤反应液,滤液水洗,饱和食盐水洗,有机相无水硫酸钠干燥,旋干溶剂,加甲醇20mL溶解,加入碳酸钾1.04g(7.54mmol),室温搅拌2h,加水,乙酸乙酯萃取,有机相水洗,饱和食盐水洗,无水硫酸钠干燥,硅胶柱层析得红色固体1.2g(74%)。
1HNMR(400MHz,CDCl3),δppm 8.04(d,J=2.0Hz,1H),7.93(d,J=2.0Hz,1H),7.79(m,4H),7.33(d,J=8.0Hz,1H),3.62(s,2H),3.31(s,1H),2.88(m,2H),2.45(brs,8H),2.29(s,3H),1.90(s,1H),1.26(m,3H).
MS(ESI),m/z:430(M++H+).
步骤6.4-乙基-3-((3-甲基-1-(2-三甲基硅基乙氧亚甲基)-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-ethyl-3-((3-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
10mL单颈瓶中加入化合物8220mg(0.5177mmol),化合物9177mg(0.5177mmol),碘化亚铜1mg(0.005mmol),二(三苯基膦)二氯化钯4mg(0.005mmol),二异丙基乙基胺134mg(1.0354mmol),DMF 2mL,置换氩气,80℃搅拌过夜,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,有机相无水硫酸钠干燥,旋干溶剂,柱层析得浅黄色固体230mg(64.4%)。MS(ESI),m/z:691(M++H+).
步骤7.4-乙基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-ethyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
将化合物10 230mg(0.3333mmol)溶于5mL 1M的四丁基氟化铵的四氢呋喃溶液中,搅拌下,加热回流过夜,加水,乙酸乙酯萃取,水洗,饱和食盐水洗,无水硫酸钠干燥,旋干溶剂,柱层析得浅黄色固体98mg(53%)。
1HNMR(400MHz,d-DMSO),δppm 13.49(s,1H),10.54(s,1H),8.68(d,J=1.6Hz,1H),8.51(d,J=1.6Hz,1H),8.21(s,1H),8.18(s,1H),8.06(d,J=8.4Hz,1H),7.95(d,J=8.0Hz,1H)7.71(d,J=8.0Hz,1H),7.53(d,J=8.4Hz,1H),3.57(s,2H),2.96(m,2H),2.54(s,3H),2.35(brs,8H),2.16(s,3H),1.31(t,J=8.0Hz,1H).
MS(ESI),m/z:561(M++H+).
实施例14
3-((1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-4-氯-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-chloro-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例13
1HNMR(400MHz,d-DMSO),δppm 13.98(s,1H),10.66(s,1H),8.73(d,J=2.0Hz,1H),8.54(d,J=2.0Hz,1H),8.33(d,J=2.0Hz,1H),8.24(s,1H),8.19(d,J=1.6Hz,1H),8.02(m,2H),7.80(d,J=7.6Hz,1H),7.71(d,J=8.8Hz,1H),3.57(m,2H),3.17(s,3H),2.40(brs,8H),2.18(s,3H).MS(ESI),m/z:554(M++H+).
实施例15
4-氯-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
4-chloro-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例13
1HNMR(400MHz,d-DMSO),δppm 13.55(s,1H),10.66(s,1H),8.69(d,J=2.0Hz,1H),8.54(d,J=1.6Hz,1H),8.32(d,J=1.6Hz,1H),8.20(s,2H),8.02(m,2H),7.81(d,J=8.8Hz,1H),7.72(d,J=8.4Hz,1H),3.58(s,2H),2.54(s,3H),2.41(s,8H),2.21(s,3H).
MS(ESI),m/z:568(M++H+).
实施例16
3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例13
1HNMR(400MHz,d-DMSO),δppm 13.51(s,1H),10.70(s,1H),8.68(d,J=1.6Hz,1H),8.51(d,J=1.6Hz,1H),8.25(s,1H),8.22(s,1H),8.13(d,J=8.0Hz,1H),8.03(d,J=8.0Hz,1H)7.81(d,J=8.0Hz,1H),7.68(m,2H),3.66(s,2H),3.10(brs,8H),2.69(s,3H),2.53(s,3H).
MS(ESI),m/z:533(M++H+).
实施例17
3-((-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-4-环丙基-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺
3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-cyclopropyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
合成方法如实施例13
1HNMR(400MHz,d-DMSO),δppm 13.50(s,1H),10.55(s,1H),8.74(d,J=2.0Hz,1H),8.53(d,J=2.0Hz,1H),8.21(m,3H),8.06(dd,J=8.4,1.6Hz,1H),8.01(dd,J=8.0,1.6Hz,1H),7.70(d,J=8.8Hz,1H),7.09(d,J=8.4Hz,1H),3.56(m,2H),2.33(brs,8H),2.15(s,3H),1.55(m,1H),1.30(m,4H).MS(ESI),m/z:559(M++H+).
实施例18
N-(3-叔丁基-5-(4-甲基-1H-咪唑-1-基)苯基)-4-甲基-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-yl)乙炔基)苯甲酰胺
N-(3-tert-butyl-5-(4-methyl-1H-imidazol-1-yl)phenyl)-4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzamide
合成方法如实施例1
1HNMR(400MHz,d-DMSO),δppm 13.50(s,1H),10.41(s,1H),8.70(s,1H),8.52(s,1H),8.20(s,1H),8.06(s,1H),7.92(m,2H),7.74(s,1H),7.52(m,1H),7.38(s,1H),7.30(s,1H),2.60(s,3H),2.54(s,3H),2.18(s,3H),1.34(s,9H).
MS(ESI),m/z:503(M++H+).
实施例19
4-甲基-3-((3-甲基-1H-吡咯并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺二甲磺酸盐
4-methyl-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide,dimesylate
将620mg 4-甲基-3-((3-甲基-1H-吡咯并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)甲基)-3-三氟甲基苯基)苯甲酰胺(1.135mmol)置于500mL单口瓶中,加入150mL无水乙醇,搅拌下滴加220mg甲磺酸(2.271mmol),室温搅拌过夜,有黄色固体析出,过滤,滤渣用乙醇洗三次,真空干燥得黄色固体70mg(84%)。
1HNMR(400MHz,d-DMSO),δppm 10.60(s,1H),8.74(d,J=2.0Hz,1H),8.69(d,J=2.0Hz,1H),8.52(d,J=2.0Hz,1H),8.25(d,J=2.0Hz,1H),8.23(s,2H),8.19(d,J=1.6Hz,1H),8.15(d,J=8.4Hz,1H),7.93(dd,J=8.0,2.0Hz,1H),7.75(d,J=8.4Hz,1H),7.54(d,J=8.4Hz,1H),3.83(s,2H),3.44(br,4H),3.08(br,4H),2.83(s,3H),2.60(s,2H),2.54(s,3H),2.36(s,6H).
MS(ESI),m/z:.547,643
实施例20
4-氯-3-((3-甲基-1H-吡唑并[3,4-b]吡啶-5-基)乙炔基)-N-(4-((4-甲基哌嗪-1-基)亚甲基)-3-(三氟甲基)苯基)苯甲酰胺二甲磺酸盐
4-chloro-3-((3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide,dimesylate
合成方法如实施例19
1HNMR(400MHz,d-DMSO),δppm 10.82(s,1H),8.70(d,J=2.0Hz,1H),8.54(d,J=2.0Hz,1H),8.34(d,J=2.0Hz,1H),8.31(s,1H),8.20(d,J=8.4Hz,1H),8.02(dd,J=8.4,2.0Hz,1H),7.87(d,J=8.4Hz,1H),7.82(d,J=8.4Hz,1H),4.23(s,2H),3.62(br,2H),3.40(br,4H),3.05(br,4H),2.87(s,3H),2.54(s,3H),2.45(s,6H).
MS(ESI),m/z:.568,664
实施例21
用不同浓度的杂环炔苯类化合物(1×10-10~1×10-5M)分别处理K562(慢性白血病),Ba/F3(携带Bcr/Abl),Ba/F3(携带T315I Bcr/Abl突变,对STI571耐受),A549(人肺癌细胞),DU145(人***癌细胞),HT-29(人结肠癌细胞)和HepG2(人肝癌细胞)等七种细胞,72小时后MTT或者CCK8,再孵育4小时,然后用酶标仪测定其在570nm(CCK8,450,650nm)的吸光值。结果发现,杂环炔苯类化合物处理可明显降低各种细胞对MTT的吸收,说明杂环炔苯类化合物可显著抑制上述细胞的增殖,尤其是抑制K562(慢性白血病),Ba/F3(携带T315IBcr/Abl突变,对STI571耐受)细胞,A549(人肺癌细胞),DU145(人***癌细胞),HT-29(人结肠癌细胞)和HepG2(人肝癌细胞)的增值,抑制率与药物浓度成正相关。根据杂环炔苯类化合物对这三种细胞的生长抑制作用,我们计算出其半数抑制浓度(IC50,μM)值如表1所描述。(所用化合物分别为实施例1-18所制备的化合物,在表1中用Drug No.标号表示)。
以上是针对本发明的可行实施例的具体说明,但该实施例并非用以限制本发明的专利范围,凡未脱离本发明技艺精神所为的等效实施或变更,均应包含于本发明的专利范围中。